Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 128

Sort by

Sort Order Select

Journal Articles

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Sang Eun Yoon, Won Seog Kim, Seok Jin Kim

Blood (2024) 144 (6): 629–638.

https://doi.org/10.1182/blood.2023023419

Published: 2024

Includes: Supplemental data

Journal Articles

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Jordan Goldstein, Won Seog Kim, Sang Eun Yoon, Seok Jin Kim, Mark Roschewski, Jason Westin, Ryan C Lynch, Stefan K. Alig, Sandra Close, Jacob J. Chabon, Davide Rossi, Wyndham H Wilson, Maximilian Diehn, Ash A. Alizadeh, David M. Kurtz

Blood (2023) 142 (Supplement 1): 187.

https://doi.org/10.1182/blood-2023-187759

Published: 2023

Journal Articles

Real-World Data of Outcome of Patients with Newly Diagnosed Bronchial-Associated Lymphoid Tissue Lymphoma: A Multi-Center Retrospective Analysis with Long-Term Survivors

Kunye Kwak, Yong Park, Byung Soo Kim, Sang Eun Yoon, Won Seog Kim, Kwai Han Yoo, Ka-Won Kang, Seok Jin Kim

Blood (2023) 142 (Supplement 1): 6143.

https://doi.org/10.1182/blood-2023-188254

Published: 2023

Journal Articles

Diverse Microbiome Characteristics in Treatment Naïve Extranodal NK/T-Cell Lymphoma Patients

Sang Eun Yoon, Woorim Kang, Junhun Cho, Jiyeon Hyeon, Seok Jin Kim, Won Seog Kim

Blood (2023) 142 (Supplement 1): 5728.

https://doi.org/10.1182/blood-2023-173788

Published: 2023

Journal Articles

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Bong-Seog Kim, Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Tae Min Kim, Eunyoung Lee, Jeong-Ok Lee, Deok-Hwan Yang, Won-Sik Lee

Blood (2023) 142 (Supplement 1): 1701.

https://doi.org/10.1182/blood-2023-173010

Published: 2023

Journal Articles

Isatuximab and Cemiplimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma: A Multi-Center, Open-Labeled Phase II Study (CISL2102/ICING study)

Seok Jin Kim, Sang Eun Yoon, Deok-Hwan Yang, Sung Yong Oh, Yoon Seok Choi, Seong Hyun Jeong, Min Kyoung Kim, Sung-Nam Lim, Junhun Cho, Won Seog Kim

Blood (2023) 142 (Supplement 1): 301.

https://doi.org/10.1182/blood-2023-174476

Published: 2023

Journal Articles

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Jun Ho Yi, Seok Jin Kim, Sang A Kim, Jongheon Jung, Dok Hyun Yoon

Blood (2023) 142 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2023-186554

Published: 2023

Journal Articles

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Seok Jin Kim, Myung-Won Lee, Sung-Nam Lim, Ka-Won Kang, Sang Eun Yoon, Yoo Jin Lee, Hye Jin Kang, Ho Sup Lee, Hyo Jung Kim, Hong Hoe Koo, Ho-Jin Shin, Hyeon-Seok Eom, Jong-Ho Won, Won Seog Kim

Blood (2023) 142 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2023-181809

Published: 2023

Journal Articles

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Blood (2023) 142 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2023-190995

Published: 2023

Journal Articles

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Brian J. Sworder, Sang Eun Yoon, Seok Jin Kim, Andre Schultz, Gregory Hogan, Sandra Close, Jacob J. Chabon, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh, Won Seog Kim

Blood (2023) 142 (Supplement 1): 69.

https://doi.org/10.1182/blood-2023-187650

Published: 2023

Journal Articles

Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patient's Journey Using Qualitative Interview

YoungJu PARK, Juhee Cho, Sooyeon Kim, Kihyun Kim, Sang Eun Yoon, Danbee Kang, Garam Bang, Nayeon Kim, Jeong Hyun Park, Seok Jin Kim

Blood (2023) 142 (Supplement 1): 5088.

https://doi.org/10.1182/blood-2023-178418

Published: 2023

Journal Articles

The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma

Sang Eun Yoon, Woorim Kang, Seunghyun Choi, Yoon Park, Mauricio Chalita, Hyun Kim, Je Hee Lee, Dong-Wook Hyun, Kyung Ju Ryu, Hojun Sung, Jae-Yun Lee, Jin-Woo Bae, Won Seog Kim, Seok Jin Kim

Blood (2023) 141 (18): 2224–2238.

https://doi.org/10.1182/blood.2022018831

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 9498–9500.

https://doi.org/10.1182/blood-2022-165716

Published: 2022

Journal Articles

Soluble MIC-a and MIC-B Analysis for the Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Yoon Sang-Eun, Junhun Cho, Yeji Jung, Booma Yabdava, Barbara Natke, Seok Jin Kim, Won Seog Kim

Blood (2022) 140 (Supplement 1): 11943–11944.

https://doi.org/10.1182/blood-2022-158874

Published: 2022

Journal Articles

Comparison of Several Salvage Treatments of Relapsed/Refractory Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis

Jinchul Kim, Jinhyun Cho, Won Seog Kim, Seok Jin Kim

Blood (2022) 140 (Supplement 1): 6711–6712.

https://doi.org/10.1182/blood-2022-168325

Published: 2022

Journal Articles

A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies

Tae Min Kim, Dok Hyun Yoon, Ahmad H. Mattour, Jorge M. Chaves, Emily Curran, Yoon Kyung Jeon, Bong-Seog Kim, Seok Jin Kim

Blood (2021) 138 (Supplement 1): 3562.

https://doi.org/10.1182/blood-2021-149927

Published: 2021

Journal Articles

Comprehensive Understanding of Gut Microbiota in Treatment Naïve Diffuse Large B Cell Lymphoma Patients

Sang Eun Yoon, Woorim Kang, Mauricio Chalita, Jeongmin Lim, Won Seog Kim, Seok Jin Kim

Blood (2021) 138 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2021-149881

Published: 2021

Journal Articles

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study

Seok Jin Kim, Jing Quan Lim, Yurike Laurensia, Junhun Cho, Sang Eun Yoon, Ji Young Lee, Kyung Ju Ryu, Young Hyeh Ko, Youngil Koh, Duck Cho, Soon Thye Lim, Marie Beck Enemark, Francesco D’Amore, Mette Bjerre, Choon Kiat Ong, Won Seog Kim

Blood (2020) 136 (24): 2754–2763.

https://doi.org/10.1182/blood.2020007247

Published: 2020

Includes: Supplemental data

Journal Articles

Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma

Hyera Kim, Hyehyun Jeong, Motoko Yamaguchi, Insuk Sohn, Sang Eun Yoon, Seonggyu Byeon, Joon Young Hur, Youngil Koh, Sung-Soo Yoon, Eo Jin Kim, Masahiko Oguchi, Kana Miyazaki, Senzo Taguchi, Dok Hyun Yoon, Junhun Cho, Young Hyeh Ko, Seok Jin Kim, Ritsuro Suzuki, Won Seog Kim

Blood (2020) 136 (22): 2548–2556.

https://doi.org/10.1182/blood.2020005026

Published: 2020

Includes: Supplemental data

Journal Articles

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

Chang Ki Min, MD PhD, Kihyun Kim, MD PhD, Seok Jin Kim, MD PhD, Dok Hyun Yoon, Sung-Soo Park, Seunghoon Han, MD PhD

Blood (2019) 134 (Supplement_1): 1847.

https://doi.org/10.1182/blood-2019-127643

Published: 2019

NARROW

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Optimizing Circulating Tumor DNA Limits of Detection for DLBCL during First Line Therapy

Real-World Data of Outcome of Patients with Newly Diagnosed Bronchial-Associated Lymphoid Tissue Lymphoma: A Multi-Center Retrospective Analysis with Long-Term Survivors

Diverse Microbiome Characteristics in Treatment Naïve Extranodal NK/T-Cell Lymphoma Patients

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Isatuximab and Cemiplimab in Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma: A Multi-Center, Open-Labeled Phase II Study (CISL2102/ICING study)

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Phase II Study of Lenalidomide Maintenance after Salvage Therapy for Relapsed or Refractory Peripheral T-Cell Lymphomas

Treatment of Relapsed/Refractory Hgbcl and Bukitt's Lymphoma with c-Myc Rearrangement: A Multi-Center, Open-Label, Phase 2 Study of PC-002 (SepB), a First-in-Class Deubiquitinase Inhibitor Inducing Myc Degradation

Prognostic Utility of Minimal Residual Disease (MRD) after Curative Intent Induction Therapy for DLBCL: A Prospective Real-World Ctdna Study

Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patient's Journey Using Qualitative Interview

The influence of microbial dysbiosis on immunochemotherapy-related efficacy and safety in diffuse large B-cell lymphoma

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Soluble MIC-a and MIC-B Analysis for the Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Comparison of Several Salvage Treatments of Relapsed/Refractory Large B-Cell Lymphoma Including Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review and Meta-Analysis

A Phase 1 Dose Escalation Study of Dual PI3K and DNA PK Inhibitor, BR101801 in Adult Patients with Advanced Hematologic Malignancies

Comprehensive Understanding of Gut Microbiota in Treatment Naïve Diffuse Large B Cell Lymphoma Patients

Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study

Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma

A Phase 1, Open-Label, Multi-Center Study of Alteminostat (CKD-581) in Combination with Lenalidomide and Dexamethasone in Patients with Previously Treated Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only